CR Double-Crane(SH:600062)2022-10-25 16:00Financial Performance - The company's operating revenue for Q3 2022 was CNY 2,247,367,643.53, representing a year-on-year increase of 0.09%[6]. - The net profit attributable to shareholders for Q3 2022 was CNY 242,045,871.54, a decrease of 17.80% compared to the same period last year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 234,539,946.15, down 15.37% year-on-year[6]. - Total operating revenue for the first three quarters of 2022 reached ¥7,158,192,142.29, an increase of 4.12% compared to ¥6,875,302,884.13 in the same period of 2021[22]. - Operating profit for the first three quarters of 2022 was ¥1,240,059,119.81, up from ¥1,093,229,461.30 in 2021, reflecting a growth of 13.43%[23]. - Net profit attributable to shareholders of the parent company for the first three quarters of 2022 was ¥978,682,608.84, compared to ¥889,041,877.58 in 2021, representing an increase of 10.06%[23]. - The company reported a net profit margin of approximately 14.26% for the first three quarters of 2022, compared to 13.45% in the same period of 2021[23]. - Basic earnings per share for the first three quarters of 2022 were ¥0.9534, an increase from ¥0.8522 in 2021, representing a growth of 11.56%[24]. Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 14,629,515,359.47, reflecting a 6.97% increase from the end of the previous year[8]. - The total liabilities decreased to CNY 7,403,909,901.76 from CNY 7,522,581,989.71, showing a reduction of about 1.58%[19]. - Total liabilities as of September 30, 2022, were ¥4,110,829,278.95, compared to ¥3,199,498,957.85 at the end of 2021, marking an increase of 28.43%[21]. - Total equity as of September 30, 2022, was ¥10,518,686,080.52, slightly up from ¥10,476,551,364.99 at the end of 2021, reflecting a growth of 0.40%[21]. Cash Flow - The company reported a net cash flow from operating activities of CNY 860,480,729.27 for the year-to-date, down 8.76% year-on-year[8]. - The net cash flow from operating activities for the first three quarters of 2022 was approximately ¥860.48 million, a decrease of 8.77% compared to ¥943.10 million in the same period of 2021[26]. - The total cash outflow from operating activities was approximately ¥5.95 billion in 2022, down 3.9% from ¥6.19 billion in 2021[26]. - The net cash flow from investment activities was approximately ¥10.56 million in 2022, a significant improvement from a negative cash flow of ¥506.35 million in 2021[27]. - The cash and cash equivalents at the end of the period increased to approximately ¥2.27 billion in 2022, compared to ¥1.56 billion in 2021, marking a growth of 45.7%[27]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 91,872[11]. - The largest shareholder, Beijing Pharmaceutical Group Co., Ltd., held 625,795,624 shares, accounting for 59.99% of the total shares[11]. - The top shareholder, He Qianchang, holds 2,184,300 shares, while the second-largest shareholder, Li Jishan, holds 2,134,500 shares[12]. - The company has not disclosed any relationships or concerted actions among the top ten unrestricted shareholders[12]. Investments and Financial Management - The company acquired 50.11% equity in Shenzhou Biotechnology Co., Ltd. on August 19, 2022, completing the transfer registration[13]. - The company also acquired 31.25% equity in Dongying Tiandong Pharmaceutical Co., Ltd. on September 26, 2022, with the board's approval on August 2, 2022[13]. - The company has entrusted financial management with a total amount of RMB 150 million, with an annualized return rate of 1.5% to 3.3%[14]. - Another entrusted financial management of RMB 200 million has an annualized return rate of 1.6% to 3.2%, with actual returns of RMB 3,093,011.31[15]. - The company has a total of RMB 250 million in entrusted financial management with an annualized return rate of 1.6% to 3.35%[16]. - The company reported a total of CNY 1,950,000,000.00 in entrusted financial management, with actual returns of CNY 12,529,589.11[18]. - The annualized yield rates for entrusted financial management products ranged from 1.3% to 3.4%[18]. - The company has plans for future entrusted financial management, indicating ongoing investment strategies[18].